FVC inadequate when assessing scleroderma lung disease

Author: Mitchel L. Zoler
Date Published: June-2014
Source: COPD Hub

PARIS – The traditional way to assess the status of interstitial lung disease in patients with systemic sclerosis, forced vital capacity, may not be the best way, based on a new analysis of 83 patients enrolled in a scleroderma-treatment trial. "A structural, physiologic, and patient-oriented composite outcome may be a more comprehensive measure of treatment response" for patients with systemic sclerosis (SSc) and interstitial lung disease, Dr. Elizabeth Volkmann said at the annual European Congress of Rheumatology.